Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 26549586

Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2015 Dec
First author
Place AE

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 Dec;16(16):1580-1. doi: 10.1016/S1470-2045(15)00451-9.
    note
    Source null
    related pmid
    26549585
    relationship
    Comment in

Authors and identifiers

  1. name
    Place AE
    type
    Author
  2. name
    Stevenson KE
    type
    Author
  3. name
    Vrooman LM
    type
    Author
  4. name
    Harris MH
    type
    Author
  5. name
    Hunt SK
    type
    Author
  6. name
    O'Brien JE
    type
    Author
  7. name
    Supko JG
    type
    Author
  8. name
    Asselin BL
    type
    Author
  9. name
    Athale UH
    type
    Author
  10. name
    Clavell LA
    type
    Author
  11. name
    Cole PD
    type
    Author
  12. name
    Kelly KM
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Place AE
    type
    Author
  2. name
    Stevenson KE
    type
    Author
  3. name
    Vrooman LM
    type
    Author
  4. name
    Harris MH
    type
    Author
  5. name
    Hunt SK
    type
    Author
  6. name
    O'Brien JE
    type
    Author
  7. name
    Supko JG
    type
    Author
  8. name
    Asselin BL
    type
    Author
  9. name
    Athale UH
    type
    Author
  10. name
    Clavell LA
    type
    Author
  11. name
    Cole PD
    type
    Author
  12. name
    Kelly KM
    type
    Author
bibliography ids
  1. nci-bib-0e8b02248ce21a77967f7290
book metadata
content sha256
f45b10dc368fb6d5b024a16e757298987bd8e1e79661f1a518a466d26746fd0d
document type
citation
dois
  1. 10.1016/S1470-2045(15)00363-0
electronic publication date
display
2015 Nov 6
precision
day
year
2015
evidence scope
bibliographic_metadata_only
id
pubmed:26549586
immutable id
pubmed:26549586@f45b10dc368fb6d5b024a16e757298987bd8e1e79661f1a518a466d26746fd0d
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
16
name
The Lancet. Oncology
nlm unique id
100957246
pages
1677-90
volume
16
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 Dec;16(16):1580-1. doi: 10.1016/S1470-2045(15)00451-9.
    note
    Source null
    related pmid
    26549585
    relationship
    Comment in
outcomes validated
false
pmid
26549586
provenance
batch id
948d34b0dea86780a31d
provider
NCBI PubMed ESummary
record sha256
50ce57b6296f7f9be8701982395335e0974be3df82bc905474e153ca5339796b
response sha256
11c34185eb9e4ea0d3c4d255d31806495349b0f097d492c4e135946541bf4bb5
retrieved at
2026-09-09T23:47:15.495091+00:00
publication date
display
2015 Dec
precision
month
year
2015
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Randomized Controlled Trial
  5. Research Support, N.I.H., Extramural
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/26549586/
title
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.

Preserved source evidence · Not medical advice